FORM 4

Check this box if no longer subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP
O 17 (1 E.IVIE. 1 1	0. 0.0.000		O IIII CO IIII

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Kelly Thomas Patrick				2. Issuer Name and Ticker or Trading Symbol Deciphera Pharmaceuticals, Inc. [DCPH]							(Che	ck all applic	ionship of Reporting Pers all applicable) Director Officer (give title below) Chief Financial		10% Ov	vner			
(Last) (First) (Middle) C/O DECIPHERA PHARMACEUTICALS, INC. 500 TOTTEN POND ROAD				3. Date of Earliest Transaction (Month/Day/Year) 02/16/2018							X	below)			Other (specify below) Officer				
(Street) WALTH	AM M	A	02451 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Inc Line)	Form f	dual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)			Execution Date,		Code (I	Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. 5)				Securitie Beneficia	Securities Beneficially Owned Following		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
					Code	v	Amount	(A) (D)	n) or Price		Transact	Transaction(s) (Instr. 3 and 4)			(111501.4)				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, ecurity or Exercise (Month/Day/Year) if any		C	Transaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
				C	ode	v	(A)	(D)	Date Exercisab		Expiration Date	Title	or	ount nber ires					
Stock Option (Right to Buy)	\$29.71	02/16/2018			A		90,000		(1)	O	2/16/2028	Common Stock	90,	.000	(1)	90,000)	D	

Explanation of Responses:

1. This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option vests in 48 equal monthly installments following the vesting commencement date of January 1, 2018, subject to continued service through such dates

Remarks:

/s/ Thomas Patrick Kelly

02/20/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.